A Study of HB0030 Injection in Patients With Advanced Solid Tumors

NCT ID: NCT05706207

Last Updated: 2023-01-31

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-21
• Study Completion Date: 2023-09-30

Brief Summary

This is a phase Ia single-center, open-label, dose escalation study.The objectives of this study are to evaluate the safety, toxicity, tolerability, pharmacokinetics/pharmacodynamics(PK/PD), immunogenicity, biomarkers, and antitumor activity of HB0030 in advanced solid tumor subjects.

Detailed Description

The phase Ia study will enroll up to 19-36 subjects with advanced solid tumor who have progressing tumor after standard therapy and have no better treatment option.The conventional 3+3 design will be applied for dose escalation.This study will set up 8 dose groups.HB0030 injection is administered once every 3 weeks.

Conditions

Advanced Solid Tumor

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1

Treatment with 0.03 mg/kg HB0030 injection administered intravenously

Group Type: EXPERIMENTAL

HB0030 injection

Intervention Type: DRUG

0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Arm 2

Treatment with 0.3 mg/kg HB0030 injection administered intravenously

Group Type: EXPERIMENTAL

HB0030 injection

Intervention Type: DRUG

0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Arm 3

Treatment with 1 mg/kg HB0030 injection administered intravenously

Group Type: EXPERIMENTAL

HB0030 injection

Intervention Type: DRUG

1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Arm 4

Treatment with 3 mg/kg HB0030 injection administered intravenously

Group Type: EXPERIMENTAL

HB0030 injection

Intervention Type: DRUG

3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Arm 5

Treatment with 10 mg/kg HB0030 injection administered intravenously

Group Type: EXPERIMENTAL

HB0030 injection

Intervention Type: DRUG

10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Arm 6

Treatment with 20 mg/kg HB0030 injection administered intravenously

Group Type: EXPERIMENTAL

HB0030 injection

Intervention Type: DRUG

20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Arm 7

Treatment with 30 mg/kg HB0030 injection administered intravenously

Group Type: EXPERIMENTAL

HB0030 injection

Intervention Type: DRUG

30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Arm 8

Treatment with 40 mg/kg HB0030 injection administered intravenously

Group Type: EXPERIMENTAL

HB0030 injection

Intervention Type: DRUG

40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Interventions

HB0030 injection

0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention Type: DRUG

HB0030 injection

0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention Type: DRUG

HB0030 injection

1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention Type: DRUG

HB0030 injection

3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention Type: DRUG

HB0030 injection

10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention Type: DRUG

HB0030 injection

20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention Type: DRUG

HB0030 injection

30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention Type: DRUG

HB0030 injection

40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention Type: DRUG

Other Intervention Names

Recombinant Humanized Anti-TIGIT Monoclonal Antibody; Recombinant Humanized Anti-TIGIT Monoclonal Antibody; Recombinant Humanized Anti-TIGIT Monoclonal Antibody; Recombinant Humanized Anti-TIGIT Monoclonal Antibody; Recombinant Humanized Anti-TIGIT Monoclonal Antibody; Recombinant Humanized Anti-TIGIT Monoclonal Antibody; Recombinant Humanized Anti-TIGIT Monoclonal Antibody; Recombinant Humanized Anti-TIGIT Monoclonal Antibody

Eligibility Criteria

Inclusion Criteria

• Male or female Age ≥ 18 years.
• Patients with histologically or cytologically confirmed advanced malignant solid tumor who have been intolerant of all standard therapies or recurrence after all standard therapies, and there is no better treatment option.
• At least one measurable tumor lesion According to RECIST criteria v1.1
• Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1
• Life expectancy ≥3 months
• Adequate organ function defined as:（No blood transfusion or hematopoietic stimulator treatment within 14 days before screening）

1. Adequate Hematological function defined as:

1. Absolute neutrophil count ≥1.5×109/L

2. Platelet count≥75×109/L

3. Hemoglobin ≥ ≥90g/L

2. Adequate hepatic function defined as:

1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

2. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN; AST or ALT ≤ 5 × ULN if subjects have liver metastases or liver cancer

3. Adequate renal function defined as:

creatinine clearance (CrCL) > 50 mL/min (calculated by Cockcroft-Gault Equation).

4. Adequate Coagulation function defined as:

1. Activated partial thromboplastin time (APTT) ≤1.5×ULN

2. International Normalized Ratio (INR)≤1.5×ULN

5. Urine protein: qualitative urine protein ≤ 1+ or qualitative urine protein≥ 2+,24h urine protein<1g

• The fertile subjects (male and female) must agree to use reliable contraceptive methods (hormone or barrier method or abstinence) with their partners during the test period and at least 90 days after the last medication; The blood or urine pregnancy test of female patients of childbearing age within 7 days before the first administration must be negative
• Subjects can fully understand this study and voluntarily sign the informed consent form before the trial, and are willing and able to follow the clinical research and follow-up visit process.

Exclusion Criteria

• Symptomatic central nervous system(CNS) metastases; or there is other evidence that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, which is not suitable for enrollment according to the judgment of the investigator; or patients with asymptomatic CNS metastases who are radiologically and neurologically stable > 4 weeks following CNS directed therapy, and are on a stable or decreasing dose of corticosteroids equivalent to < 10 mg prednisone/day for at least 2 weeks prior to study treatment are eligible for study entry.
• Active autoimmune disease or history of autoimmune disease requiring systemic therapy < 2 years prior to screening except hypothyroidism, vitiligo, Grave's disease, Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that has not been active in the 2 years prior to study screening are eligible.
• History of Grade 3-4 immune-related adverse events (irAEs) or irAEs requiring discontinuation of prior therapies, (except for grade 3 endocrinopathy that is managed with hormone replacement therapy).
• Use of systemic corticosteroids in a dose equivalent to > 10 mg/day of prednisone or other immunosuppressive agent < 2 weeks prior to screening; the use of topical, intraocular, intra-articular, intranasal or inhaled corticosteroids (systemic absorption is low) will be allowed to prevent (e.g. allergy to contrast agents) or treat non-autoimmune condition (e.g. delayed hypersensitivity caused by exposure to allergens)
• Patients who Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

1. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months before enrollment

2. Serious cardiac rhythm or conduction abnormality, such as ventricular arrhythmia requiring clinical intervention, II-III degree atrioventricular block, QTcF≥450 ms, etc

3. New York Heart Association（NYHA）cardiac function grade ≥ Grade II or left ventricular ejection fraction(LVEF)<50%

4. Uncontrolled arterial hypertension even after standard treatment (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg)

• Uncontrolled diabetes mellitus with hemoglobin A1c > 8%.
• Patients who Have received TIGIT inhibitor treatment in the past
• Patients who Have received chemotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor drugs within 4 weeks before enrollment， Except for the following：

1. Nitrosourea or mitomycin C within 6 weeks before the first use of the study drug

2. Oral fluorouracil and small molecule targeted drugs are taken 2 weeks before the first use of the study drug or within 5 half-life of the drug(according to whichever is longer)

3. The Chinese medicine with anti-tumor indication is within 2 weeks before the first use of the study drug

• Patients who Have received stem cell, bone marrow or solid organ transplantation in the past
• Any of the following infections：

1. Active infection within 2 weeks before screening, requiring intravenous medication

2. Active tuberculosis (via medical history).

3. Positive test for HIV antibody at screening.

4. Active hepatitis B or C. HBV carriers without active disease (HBV DNA titer < 1000 cps/mL or 200 IU/mL), or cured Hepatitis C (negative hepatitis C virus RNA test) may be enrolled.

• patients who have received major surgical treatment (excluding diagnostic puncture, venous catheterization, etc.), interventional treatment, radiotherapy and ablation treatment within 4 weeks before screening
• patients who have a history of severe allergy, has experienced 3-4 grade allergic reaction when receiving other monoclonal antibodies, or is known to be allergic to protein drugs or recombinant proteins or HB0030 drug components
• Patients who have received live virus vaccine within 30 days before screening except for Corona Virus Disease 2019(COVID-19) vaccine
• Pregnant or breast-feeding females
• Patient who has participated in other clinical studies and received study drugs within 30 days before the first dose Administration of study.
• Any other serious diseases (e.g. active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe symptoms and signs of blood coagulation disorder, heart disease).or in the judgment of the Investigator, there are some situation may interfere with the planned staging, treatment and follow-up. Or The patient's compliance is affected or the subject is at high risk of treatment complications.
• COVID-19 infected persons with positive quantitative real time(qRT) polymerase chain reaction(PCR )and/or serological test results during screening.
• Severe dyspnea or pulmonary dysfunction or need for continuous supportive oxygen inhalation.
• The skin wound, surgical site, wound site, mucosa serious ulcer or fracture did not fully heal, and the investigator judged that it was not suitable for enrollment.
• Patients with gastrointestinal bleeding within 12 weeks before the administration of the first study drug or with active gastrointestinal bleeding judged by the investigator.
• Patients with a history of interstitial lung disease or non-infectious pneumonia, except those caused by radiotherapy (enrollment shall be determined after discussion with the medical supervisor)
• Inability to comply with study and follow-up procedures
• Patients unable to comply with study procedures
• Patients who in the judgement of the Investigator are not suited to participate in this trial

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Affiliated Hospital of Bengbu Medical University

OTHER

Sponsor Role: collaborator

Huabo Biopharm Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

huan zhou, master

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital of Bengbu Medical University

Locations

the First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China

Site Status: RECRUITING

Countries

China

Central Contacts

huan zhou, Master

Role: CONTACT

Phone: +8613665527160

Email: zhouhuanbest@vip.163.com

Facility Contacts

huan zhou, master

Role: primary

Other Identifiers

HB0030-01

Identifier Type: -

Identifier Source: org_study_id